Q1 FY27 results approved, acquisition of manufacturing unit for Rs 29.98 cr
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 5.1 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 results: revenue Rs 32.58 cr (up 53 percent YoY), profit Rs 5.74 cr (up 252 percent YoY), EPS Rs 4.98. Also approved purchase of a manufacturing facility at Mandideep, Madhya Pradesh from Kaygee Laboratories Pvt Ltd, a promoter group company (related party), for Rs 29.98 cr on slump sale basis. The unit makes chemical intermediates and APIs currently supplied to the company on job work basis. Deal is at arms length per independent valuer, subject to shareholder approval, with completion expected by Nov 30, 2026.
Vertical integration move to secure supply chain and cut outsourcing costs. Related party deal needs shareholder approval.